VRDN vs. RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, PRVA, VCYT, and HTFL
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Privia Health Group (PRVA), Veracyte (VCYT), and Heartflow (HTFL). These companies are all part of the "healthcare" industry.
Viridian Therapeutics vs. Its Competitors
Viridian Therapeutics (NASDAQ:VRDN) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.
Viridian Therapeutics currently has a consensus target price of $37.78, indicating a potential upside of 109.76%. RadNet has a consensus target price of $76.80, indicating a potential upside of 2.41%. Given Viridian Therapeutics' higher possible upside, equities analysts clearly believe Viridian Therapeutics is more favorable than RadNet.
Viridian Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.
In the previous week, RadNet had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 14 mentions for RadNet and 6 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat RadNet's score of 1.08 indicating that Viridian Therapeutics is being referred to more favorably in the media.
RadNet has a net margin of -0.78% compared to Viridian Therapeutics' net margin of -112,806.88%. RadNet's return on equity of 2.41% beat Viridian Therapeutics' return on equity.
77.9% of RadNet shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by insiders. Comparatively, 5.6% of RadNet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
RadNet beats Viridian Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VRDN) was last updated on 9/16/2025 by MarketBeat.com Staff
